Jeffs’ Brands Partners with Deliverz.AI for Healthcare Robotics Venture in $84.8B Market

Jeffs’ Brands Partners with Deliverz.AI for Healthcare Robotics Venture in .8B Market




Jeffs’ Brands (Nasdaq: JFBR) has signed a binding Letter of Intent with Deliverz.AI to establish a joint venture for AI-powered autonomous robotic solutions in U.S. healthcare logistics. The JV structure involves Deliverz.AI contributing technology licenses for 50% equity and Jeffs’ Brands investing $1 million for the other 50%. Deliverz.AI’s robot Polly is currently operational at Sheba Medical Center, delivering chemotherapy drugs autonomously. The service robotics market is projected to grow from $41.5 billion in 2023 to $84.8 billion by 2028. The definitive agreement is expected within 30 days, subject to due diligence and regulatory approvals.

Jeffs’ Brands (Nasdaq: JFBR) ha firmato una Lettera di Intenti vincolante con Deliverz.AI per stabilire una joint venture per soluzioni robotiche autonome alimentate dall’intelligenza artificiale nella logistica sanitaria negli Stati Uniti. La struttura della joint venture prevede che Deliverz.AI contribuisca con licenze tecnologiche per il 50% del capitale e Jeffs’ Brands investa 1 milione di dollari per il restante 50%. Il robot Polly di Deliverz.AI è attualmente operativo presso il Sheba Medical Center, consegnando autonomamente farmaci chemioterapici. Si prevede che il mercato della robotica di servizio crescerà da 41,5 miliardi di dollari nel 2023 a 84,8 miliardi di dollari entro il 2028. L’accordo definitivo è atteso entro 30 giorni, soggetto a due diligence e approvazioni normative.

Jeffs’ Brands (Nasdaq: JFBR) ha firmado una Carta de Intenciones vinculante con Deliverz.AI para establecer una empresa conjunta de soluciones robóticas autónomas impulsadas por inteligencia artificial en la logística sanitaria de EE. UU. La estructura de la empresa conjunta implica que Deliverz.AI contribuya con licencias tecnológicas por el 50% de la equidad y que Jeffs’ Brands invierta 1 millón de dólares por el otro 50%. El robot Polly de Deliverz.AI está actualmente operativo en el Sheba Medical Center, entregando medicamentos de quimioterapia de manera autónoma. Se proyecta que el mercado de la robótica de servicios crezca de 41.5 mil millones de dólares en 2023 a 84.8 mil millones de dólares para 2028. Se espera que el acuerdo definitivo se firme en un plazo de 30 días, sujeto a la diligencia debida y aprobaciones regulatorias.

제프스 브랜드 (Nasdaq: JFBR)는 딜리버즈.AI와 미국 의료 물류에서 AI 기반 자율 로봇 솔루션을 구축하기 위한 구속력 있는 의향서를 체결했습니다. JV 구조는 딜리버즈.AI가 50%의 지분에 대한 기술 라이센스를 제공하고 제프스 브랜드가 나머지 50%에 대해 100만 달러를 투자하는 방식입니다. 딜리버즈.AI의 로봇 폴리는 현재 쉐바 의료 센터에서 자율적으로 화학 요법 약물을 전달하고 있습니다. 서비스 로봇 시장은 2023년 415억 달러에서 2028년에는 848억 달러로 성장할 것으로 예상됩니다. 최종 계약은 실사가 완료되고 규제 승인이 이루어지는 대로 30일 이내에 체결될 것으로 보입니다.

Jeffs’ Brands (Nasdaq: JFBR) a signé une Lettre d’Intention contraignante avec Deliverz.AI pour établir une coentreprise consacrée aux solutions robotiques autonomes alimentées par l’IA dans la logistique de la santé aux États-Unis. La structure de la coentreprise implique que Deliverz.AI contribue des licences technologiques pour 50% des actions et que Jeffs’ Brands investisse 1 million de dollars pour les 50% restants. Le robot Polly de Deliverz.AI est actuellement opérationnel au Sheba Medical Center, livrant des médicaments de chimiothérapie de manière autonome. Le marché de la robotique de service devrait passer de 41,5 milliards de dollars en 2023 à 84,8 milliards de dollars d’ici 2028. L’accord définitif est attendu dans un délai de 30 jours, sous réserve de la diligence raisonnable et des approbations réglementaires.

Jeffs’ Brands (Nasdaq: JFBR) hat einen verbindlichen Letter of Intent mit Deliverz.AI unterzeichnet, um ein Joint Venture für KI-gestützte autonome Robotiklösungen im Gesundheitslogistikbereich in den USA zu gründen. Die Struktur des Joint Ventures sieht vor, dass Deliverz.AI Technologie-Lizenzen für 50% des Eigenkapitals beiträgt und Jeffs’ Brands 1 Million Dollar für die anderen 50% investiert. Der Roboter Polly von Deliverz.AI ist derzeit im Sheba Medical Center im Einsatz und liefert autonom Chemotherapiedrogen. Der Markt für Servicerobotik wird voraussichtlich von 41,5 Milliarden Dollar im Jahr 2023 auf 84,8 Milliarden Dollar im Jahr 2028 wachsen. Der endgültige Vertrag wird innerhalb von 30 Tagen erwartet, vorbehaltlich Due Diligence und regulatorischer Genehmigungen.

Positive


  • Market opportunity in service robotics sector projected to reach $84.8 billion by 2028

  • Partnership with established AI robotics company already operating in top-ranked hospital

  • Structured investment approach with milestone-based payments reducing initial risk

Negative


  • Significant capital commitment of $1 million required from Jeffs’ Brands

  • No guarantee of JV completion or success

  • Potential deal termination if due diligence results are unsatisfactory

Insights


This strategic joint venture marks a significant entry into the rapidly growing service robotics market, projected to reach $84.8 billion by 2028. The partnership leverages Deliverz.AI’s proven technology, already operational in a top-tier medical facility, with Jeffs’ Brands’ $1 million investment and market presence. The phased investment approach, starting with $100,000 initial commitment, demonstrates a calculated risk management strategy.

The existing deployment at Sheba Medical Center provides important validation of the technology’s reliability in critical healthcare applications. However, the U.S. market entry faces unique regulatory and operational challenges. The structured payment schedule tied to milestone achievements suggests a pragmatic approach to market expansion, though success will heavily depend on securing pilot projects and navigating the complex U.S. healthcare system.

The autonomous delivery of chemotherapy drugs represents a high-value application in healthcare logistics, addressing critical safety and efficiency needs. The technology’s successful implementation at a globally ranked hospital provides strong credibility for U.S. market entry. Key differentiators include:

  • Indoor/outdoor navigation capabilities essential for complex hospital environments
  • AI-powered platforms enabling workflow optimization
  • Proven track record in handling sensitive medical deliveries

The timing aligns with increasing adoption of robotics in healthcare, particularly post-pandemic emphasis on automation. However, U.S. healthcare facilities may require extensive validation and compliance processes before adoption.












Deliverz.AI flagship robot, Polly, is already in use at Israel’s Sheba Medical Center, ranked the 9th best hospital in the world, according to Newsweek magazine, where it autonomously delivers chemotherapy drugs across complex hospital environments

Tel Aviv, Israel, Nov. 27, 2024 (GLOBE NEWSWIRE) — Jeffs’ Brands Ltd (“Jeffs’ Brands” or the “Company”) (Nasdaq: JFBR, JFBRW), a data-driven e-commerce company operating on the Amazon Marketplace, announced today that it has entered into a binding Letter of Intent (“LOI”) with Deliverz.AI Ltd. (“Deliverz.AI”), a company focused on artificial intelligence (“AI”) powered fully autonomous multi-purpose robotic platforms. The LOI outlines a plan to establish a joint venture (“JV”) to operate exclusively in the United States, combining the strengths of both companies to introduce AI-powered fully autonomous robotic solutions for healthcare logistics in the United States.

Deliverz.AI specializes in autonomous navigation platforms that streamline logistics operations. Their flagship robot, Polly, is already in use at Israel’s Sheba Medical Center, ranked by Newsweek magazine as the 9th best hospital in the world, where it autonomously delivers chemotherapy drugs across complex hospital environments. The company’s AI-powered platforms are designed for seamless indoor and outdoor navigation, optimizing workflows in healthcare, smart cities, and Industry 4.0 applications.

The service robotics market is projected to reach $84.8 billion by 2028 growing from $41.5 billion in 2023, according to MarketandMarkets. The growing adoption of robots for new applications, the surging use of Interest of Things (IoT) in robots for cost effective predictive medicine and the increasing use of disinfection robots in hospitals are factors driving the growth of this market per MarketandMarkets.

Pursuant to the LOI, Deliverz.AI will provide the license for its proprietary robotics technology and operational software to the JV in consideration of a 50% equity stake in the JV, while Jeffs’ Brands will invest $1 million for a 50% equity stake in the JV. The investment will be paid according to a phased schedule: $100,000 upon the signing of the definitive agreement establishing the JV, $100,000 when the JV secures its first U.S. pilot project, and the remaining $800,000 will be paid in installments until the end of 2025, based on budgets to be agreed upon in the definitive agreement.

The JV will aim to partner with U.S. medical centers, deploying robotics solutions to improve logistics efficiency and enhance healthcare delivery. Both companies are committed to finalizing definitive agreements within 30 days, which will include customary closing conditions, compliance with any regulatory approvals and subject to satisfactory due diligence to be completed by each party. In the event that the results of the due diligence are not satisfactory to one of the parties, the LOI will terminate. There is no guarantee when or if the JV will be completed or if the JV will be successful.

About Jeffs’ Brands Ltd

Jeffs’ Brands aims to transform the world of e-commerce by creating and acquiring products and turning them into market leaders, tapping into vast, unrealized growth potential. Through the Company’s management team’s insight into the FBA Amazon business model, it aims to use both human capability and advanced technology to take products to the next level. For more information on Jeffs’ Brands Ltd visit https://jeffsbrands.com.

Forward-Looking Statement Disclaimer

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “should,” “could,” “seek,” “intend,” “plan,” “goal,” “estimate,” “anticipate” or other comparable terms. For example, we are using forward-looking statements when discussing the JV, which is subject to the execution of binding definitive agreements and the completion of satisfactory due diligence, the establishment of the JV and the commencement of its operations in the U.S., including partnering with U.S. medical centers and the projected growth in the service robotics market. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: our ability to adapt to significant future alterations in Amazon’s policies; our ability to sell our existing products and grow our brands and product offerings, including by acquiring new brands; our ability to meet our expectations regarding the revenue growth and the demand for e-commerce; the overall global economic environment; the impact of competition and new e-commerce technologies; general market, political and economic conditions in the countries in which we operate; projected capital expenditures and liquidity; the impact of possible changes in Amazon’s policies and terms of use; the impact of the conditions in Israel, including the recent attacks by Hamas, Iran, and other terrorist organizations; and the other risks and uncertainties described in the Company’s Annual Report on Form 20-F for the year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission (“SEC”), on April 1, 2024 and our other filings with the SEC. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investor Relations Contact:

Michal Efraty
Adi and Michal PR- IR
Investor Relations, Israel
[email protected]









FAQ



What is the investment structure of the Jeffs’ Brands (JFBR) and Deliverz.AI joint venture?


Jeffs’ Brands will invest $1 million for 50% equity, while Deliverz.AI will provide technology licenses for the other 50% equity stake in the joint venture.


Where is Deliverz.AI’s robot Polly currently being used?


Polly is currently operating at Israel’s Sheba Medical Center, ranked as the 9th best hospital globally by Newsweek, delivering chemotherapy drugs autonomously.


What is the projected growth of the service robotics market according to the JFBR announcement?


The service robotics market is expected to grow from $41.5 billion in 2023 to $84.8 billion by 2028.


When will Jeffs’ Brands (JFBR) complete the joint venture agreement with Deliverz.AI?


The companies aim to finalize definitive agreements within 30 days, subject to due diligence and regulatory approvals.





link